- Home
- ALLO vs NBH Comparison
ALLO vs NBH Comparison
Compare ALLO & NBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- NBH
- Stock Information
- Founded
- ALLO 2017
- NBH 2002
- Country
- ALLO United States
- NBH United States
- Employees
- ALLO N/A
- NBH N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- NBH Finance/Investors Services
- Sector
- ALLO Health Care
- NBH Finance
- Exchange
- ALLO Nasdaq
- NBH Nasdaq
- Market Cap
- ALLO 338.9M
- NBH 291.1M
- IPO Year
- ALLO 2018
- NBH N/A
- Fundamental
- Price
- ALLO $1.55
- NBH $10.12
- Analyst Decision
- ALLO Strong Buy
- NBH
- Analyst Count
- ALLO 10
- NBH 0
- Target Price
- ALLO $9.66
- NBH N/A
- AVG Volume (30 Days)
- ALLO 2.6M
- NBH 85.9K
- Earning Date
- ALLO 05-12-2025
- NBH 01-01-0001
- Dividend Yield
- ALLO N/A
- NBH 4.34%
- EPS Growth
- ALLO N/A
- NBH N/A
- EPS
- ALLO N/A
- NBH 0.12
- Revenue
- ALLO $22,000.00
- NBH N/A
- Revenue This Year
- ALLO N/A
- NBH N/A
- Revenue Next Year
- ALLO $9.07
- NBH N/A
- P/E Ratio
- ALLO N/A
- NBH $87.04
- Revenue Growth
- ALLO N/A
- NBH N/A
- 52 Week Low
- ALLO $1.23
- NBH $8.75
- 52 Week High
- ALLO $3.78
- NBH $11.01
- Technical
- Relative Strength Index (RSI)
- ALLO 49.84
- NBH 50.95
- Support Level
- ALLO $1.38
- NBH $9.68
- Resistance Level
- ALLO $1.75
- NBH $9.98
- Average True Range (ATR)
- ALLO 0.13
- NBH 0.20
- MACD
- ALLO 0.04
- NBH 0.03
- Stochastic Oscillator
- ALLO 61.54
- NBH 72.67
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.